AB
ACRV icon

Amalgamated Bank’s Acrivon Therapeutics ACRV Stock Holding History

Amalgamated Bank’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-378
Closed -$1K – 3011
2025
Q1 		$1K Hold
378
– – ﹤0.01% 2893
2024
Q4 		$2K Hold
378
– – ﹤0.01% 2892
2024
Q3 		$3K Hold
378
– – ﹤0.01% 2861
2024
Q2 		$2K Hold
378
– – ﹤0.01% 2945
2024
Q1 		$3K Sell
378
-853
-69% -$3.96K ﹤0.01% 2808
2023
Q4 		$6K Sell
1,231
-113
-8% -$597 ﹤0.01% 2922
2023
Q3 		$13K Buy
1,344
+563
+72% +$6.5K ﹤0.01% 2826
2023
Q2 		$10K Sell
781
-349
-31% -$4.22K ﹤0.01% 2949
2023
Q1 		$14K Buy
+1,130
New +$19K ﹤0.01% 2749

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Amalgamated Bank's ACRV Position: Q2 2025 in Review

Amalgamated Bank sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 378 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $14K in Q1 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Amalgamated Bank reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 378 Acrivon Therapeutics shares in Q2 2025, an estimated $1K.
  • Amalgamated Bank first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
  • Amalgamated Bank's Acrivon Therapeutics position peaked at $14K in Q1 2023.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.